• 1
    The Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from the organized service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers Prev. 2006; 15: 52-56.
  • 2
    Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 24: 966-978.
  • 3
    American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2010.
  • 4
    Gallager HS, Martin JE. The study of mammary carcinoma by mammography and whole organ sectioning. Early observations. Cancer. 1969; 23: 855-873.
  • 5
    Egan RL. Multicentric breast carcinoma: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer. 1982; 49: 1123-1130.
  • 6
    Holland R, Veiling SH, Mravunac M, et al. Histologic multifocality of Tis, T1-2 breast carcinomas Implications for clinical trials of breast conserving surgery. Cancer. 1985; 56: 979-990.
  • 7
    Tabar L, Tot T, Dean PB. Breast Cancer: The Art and Science of Early Detection by Mammography: Perception, Interpretation, Histopathologic Correlation. Stuttgart, Germany: Thieme; 2005.
  • 8
    Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol. 2005; 23: 7497-7502.
  • 9
    Cabioglu N, Ozmen V, Kaya H, et al. Increased lymph node positivity in multifocal and multicentric breast cancer [serial online]. J Am Coll Surg. 2009; 208: 67-74.
  • 10
    Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of 2 large European randomized trials. J Clin Oncol. 2001; 19: 1688-1697.
  • 11
    Lindquist D, Hellberg D, Tot T. Disease extent ≥4 cm is a prognostic marker of local recurrence in T1-2 breast cancer [serial online]. Patholog Res Int. 2011; 2011: 860584.
  • 12
    Tot T, Gere M, Pekar Gy, et al. Breast cancer multifocality, disease extent, and survival. Hum Pathol. 2011; 42: 1761-1769.
  • 13
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000; 406: 747-752.
  • 14
    Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2009; 220: 263-280.
  • 15
    Sorlie T, Perou CM, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006; 5: 2914-2918.
  • 16
    Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007; 356: 217-226.
  • 17
    Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 2006; 12: 6459-6468.
  • 18
    Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from large cohort study. Breast Cancer Res Treat. 2011; 126: 185-192.
  • 19
    Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736-1747.
  • 20
    Lopez-Garcia MA, Geyer FC, Natrajan R, et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol. 2010; 222: 64-75.
  • 21
    Weigelt B, Geyer FC, Natrajan R, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010; 220: 45-57.
  • 22
    Foulkes WD, Smith IE, Reis-Filho JR. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948.
  • 23
    Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012; 131: 1061-1066.
  • 24
    Wetterskog D, Lopez-Garcia MA, Lambros MB, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol. 2012; 226: 84-96.
  • 25
    Tot T, Pekar G. Multifocality in “basal-like” breast carcinomas and its influence on lymph node status. Ann Surg. Oncol. 2011; 18: 1671-1677.
  • 26
    Tot T. Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes. Clin Breast Cancer. 2011; 11: 258-263.
  • 27
    Tot T, Tabar L, Dean PB. Practical Breast Pathology. Stuttgart, Germany: Thieme; 2002.
  • 28
    Tot T. The clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histological sections. Cancer. 2007; 110: 2551-2560.
  • 29
    Choi Y, Kim EJ, Seol H, et al. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast. Hum Pathol. 2012; 43: 48-55.
  • 30
    Hu Z, Fan C, Oh DS, Marron JS, et al. The molecular portraits of breast tumors are conserved across microarray platforms [serial online]. BMC Genomics. 2006; 7: 96.
  • 31
    Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterisation of histological special types. J Pathol. 2008; 216: 141-150.
  • 32
    Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool breast cancer management: are we there yet? Int J Surg Pathol. 2009; 17: 285-302.
  • 33
    Geyer F, Lopez-Garcia MA, Lambros MB, et al. Genetic characterisation of breast cancer and implications for clinical management. J Cell Mol Med. 2009; 13: 4090-4103.
  • 34
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.
  • 35
    Galea MH, Blamey RW, Elston CE, et al. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 1992; 22: 208-219.
  • 36
    Heimann R, Hellman S. Clinical progression of breast cancer malignant behaviour: what to expect and when to expect it. J Clin Oncol. 2000; 18: 591-599.
  • 37
    Weissenbacher TM, Zschage M, Janni W, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010; 122: 27-34.
  • 38
    Joergensen LE, Gunnarsdottir KA, Lanng C, et al. Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996-2001. Breast. 2008; 17: 587-591.
  • 39
    Biesemier KW, Alexander CM. Enhancement of mammographic-pathologic correlation utilizing large format histology for malignant breast diseases. Semin Breast Dis. 2005; 8: 152-162.
  • 40
    Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008; 26: 1-10.
  • 41
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
  • 42
    Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by 5 biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376.